1 / 10

Gout Therapeutics Market

The worldwide gout therapeutics industry was quite large in 2021, and it is predicted to grow at a steady rate throughout the projected timeline. Changing lifestyles, a growing elderly population, a rise in the number of people suffering from severe gout, increased research and development efforts, and technical advancements in biologics to cure and control the illness amongst patients globally are driving industry revenue expansion.

Ronald15
Download Presentation

Gout Therapeutics Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Gout Therapeutics Market Market Size Worth $7.63 Billion by 2029 | CAGR: 13.7%

  2. Gout Therapeutics Market Size Worth $7.63 Billion by 2029 | CAGR: 13.7% “As per Polaris Market Research report, Gout Therapeutics Market is attending major innovations & transformations and is projected to reach $7.63 Billion by 2029 | CAGR: 13.7% during the conjecture period 2021 to 2028.” The global Gout Therapeutics Market report scrutinizes the present situation and development prognosis of the market. The report offers a complete knowledge of key parameters such as market size, share and growth, trends, cost structure, and comprehensive and statistical data in the global Gout Therapeutics Market. Also, the market overview section of the report holds an in-depth analysis of current and future trends, analyzing the data on a historical basis and forecasted data till the year 2028. The report traces key market drivers, covering potentially lucrative opportunities and challenges as well as drivers, obstacles, issues, and risks. ➢Gout Therapeutics Market Report Scope: The global Gout Therapeutics Market is segmented ByDrug Class, By Disease Condition, By Region. The research report analyzes the most important trends related to the different segments that help to explain the market. The report additionally surveys both developed & developing regions considered for global Gout Therapeutics Market research. The regional analysis engages readers with a comprehensive overview of various countries and regions to help players plan effective expansion strategies. The report outlines the noteworthy factors, such as driving factors and challenges, that will explain the market’s future growth. Also, it covers an exhaustive coverage of major industry drivers, restraints, and their impact on global Gout Therapeutics Market growth during the forecast period from 2021-2028. The market research assists in studying the key plans, initiatives, and strategies for the development of the market. - 2 -

  3. Gout Therapeutics Market Size Worth $7.63 Billion by 2029 | CAGR: 13.7% By Drug Class By Region By Disease Condition •Non-steroidal Anti-Inflammatory Drugs (NSAIDs) •Acute •North America (U.S., Canada) •Corticosteroids •Chronic •Europe (Germany, UK, France, Italy, Spain, Belgium, •Colchicine Austria, Netherlands) •Asia-Pacific (China, India, Japan, South Korea, •Urate Lowering Agents Australia, Malaysia, Indonesia) •Latin America (Brazil, Mexico, Argentina) •Middle East and Africa (South Africa, Saudi Arabia, UAE, Israel) ➢COVID-19 Impact Analysis for Gout Therapeutics Market The market has also been affected by the recent COVID-19 pandemic and is expected to experience its long- term effects over the forecast period. Extensive evaluation of the effect of the COVID-19 pandemic is given to uncover the major issues and potential paths forward. The report merges the customer spending habits, business target, dynamics of current market forces, re-routing of the supply chain, and competitors in the global Gout Therapeutics Market as a thorough analysis. The report serves overall estimation, insights, and forecasts, considering the COVID-19 impact on the market. Gain access to our latest research report that includes in-depth analysis of the COVID-19 pandemic impacting the the Gout Therapeutics Market across different regions and how major players are building strategies to mitigate the adverse effect of the pandemic and take benefit of emerging opportunities ➢Regional Outlook In terms of geography, the region dominated the market with its higher revenue share contribution. The driving factors for this regional market growth include the current technological advancements in the industry, growing economic stability, huge government investments, and rising awareness related to the benefits of the product/service. ➢Browse Detailed Research Report on Gout Therapeutics Market Analysis: https://www.polarismarketresearch.com/industry-analysis/gout-therapeutics-market ➢Competitive Landscape The report completely profiles prominent market players or industrialists covering company profile, product specifications, production capacity/sales, revenue, price, and gross margin & sales. Here you will find a comprehensive analysis of the competitive landscape and detailed information on vendors and factors that - 3 -

  4. Gout Therapeutics Market Size Worth $7.63 Billion by 2029 | CAGR: 13.7% will challenge the growth of major vendors. The section highlights key points such as regional segmentation, major investments, and details of historical, present, and projected revenues. the product portfolio, market explanation, and classification are indicated. According to Polaris Market Research, the leading players with a noteworthy dominance in the Gout Therapeutics Market include Ablynx, Antares Pharma, Astellas Pharma, AstraZeneca, Boehringer Ingelheim, CymaBay Therapeutics, Eisai, Eli Lilly, GlaxoSmithKline, Horizon Pharma, JW Pharmaceutical, LG Life Sciences, Merck, Novartis, Novo Nordisk, Regeneron Pharmaceuticals, Sandoz, Sanofi, Takeda Pharmaceuticals, Teijin Pharma, and Vertex Pharmaceuticals. https://www.polarismarketresearch.com/industry-analysis/gout-therapeutics- Request for sample: market/request-for-sample Table of Contents 1.Introduction 1.1. Report Description 1.1.1. Objectives of the Study 1.1.2. Market Scope 1.1.3. Assumptions 1.2. Stakeholders 2.Executive Summary 2.1. Market Highlights 3.Research Methodology 3.1. Overview 3.1.1. Data Mining 3.2. Data Sources 3.2.1. Primary Sources 3.2.2. Secondary Sources 4.Gout Therapeutics Market Insights 4.1. Gout Therapeutics Market – Industry Snapshot 4.2. Gout Therapeutics Market Dynamics 4.2.1. Drivers and Opportunities 4.2.2. Restraints and Challenges 4.3.Porter’s Five Forces Analysis 4.3.1. Bargaining Power of Suppliers (Moderate) 4.3.2. Threats of New Entrants: (Low) 4.3.3. Bargaining Power of Buyers (Moderate) 4.3.4. Threat of Substitute (Moderate) 4.3.5. Rivalry among existing firms (High) 4.4. PESTLE Analysis 4.5.Value Chain Analysis 4.6. Gout Therapeutics Industry trends 4.7. COVID-19 Impact Analysis 5.Global Gout Therapeutics Market, by Drug Class 5.1. Key Findings 5.2. Introduction 5.2.1. Global Gout Therapeutics, by Drug Class, 2017 - 2029 (USD Billion) 5.3.Non-steroidal Anti-Inflammatory Drugs (NSAIDs) - 4 -

  5. Gout Therapeutics Market Size Worth $7.63 Billion by 2029 | CAGR: 13.7% 5.3.1. Global Gout Therapeutics Market, by Non-steroidal Anti-Inflammatory Drugs (NSAIDs), by Region, 2017 - 2029 (USD Billion) 5.4.Corticosteroids 5.4.1. Global Gout Therapeutics Market, by Corticosteroids, by Region, 2017 - 2029 (USD Billion) 5.5.Colchicine 5.5.1. Global Gout Therapeutics Market, by Colchicine, by Region, 2017 - 2029 (USD Billion) 5.6.Urate Lowering Agents 5.6.1. Global Gout Therapeutics Market, by Urate Lowering Agents, by Region, 2017 - 2029 (USD Billion) 6.Global Gout Therapeutics Market, by Disease Condition 6.1. Key Findings 6.2. Introduction 6.2.1. Global Gout Therapeutics Market, by Disease Condition, 2017 - 2029 (USD Billion) 6.3.Acute 6.3.1. Global Gout Therapeutics Market, by Acute, by Region, 2017 - 2029 (USD Billion) 6.4.Chronic 6.4.1. Global Gout Therapeutics Market, by Chronic, by Region, 2017 - 2029 (USD Billion) 7.Global Gout Therapeutics Market, by Geography 7.1. Key findings 7.2. Introduction 7.2.1. Gout Therapeutics Market Assessment, By Geography, 2017 - 2029 (USD Billion) 7.3. Gout Therapeutics Market – North America 7.3.1. North America: Gout Therapeutics Market, by Disease Condition, 2017 - 2029 (USD Billion) 7.3.2. North America: Gout Therapeutics Market, by Drug Class, 2017 - 2029 (USD Billion) 7.3.3. Gout Therapeutics Market – U.S. 7.3.3.1. U.S.: Gout Therapeutics Market, by Disease Condition, 2017 - 2029 (USD Billion) 7.3.3.2. U.S.: Gout Therapeutics Market, by Drug Class, 2017 - 2029 (USD Billion) 7.3.4. Gout Therapeutics Market – Canada 7.3.4.1. Canada: Gout Therapeutics Market, by Disease Condition, 2017 - 2029 (USD Billion) 7.3.4.2. Canada: Gout Therapeutics Market, by Drug Class, 2017 - 2029 (USD Billion) 7.4. Gout Therapeutics Market – Europe 7.4.1. Europe: Gout Therapeutics Market, by Disease Condition, 2017 - 2029 (USD Billion) 7.4.2. Europe: Gout Therapeutics Market, by Drug Class, 2017 - 2029 (USD Billion) 7.4.3. Gout Therapeutics Market – UK 7.4.3.1. UK: Gout Therapeutics Market, by Disease Condition, 2017 - 2029 (USD Billion) 7.4.3.2. UK: Gout Therapeutics Market, by Drug Class, 2017 - 2029 (USD Billion) 7.4.4. Gout Therapeutics Market – France 7.4.4.1. France: Gout Therapeutics Market, by Disease Condition, 2017 - 2029 (USD Billion) 7.4.4.2. France: Gout Therapeutics Market, by Drug Class, 2017 - 2029 (USD Billion) 7.4.5. Gout Therapeutics Market – Germany - 5 -

  6. Gout Therapeutics Market Size Worth $7.63 Billion by 2029 | CAGR: 13.7% Germany: Gout Therapeutics Market, by Disease Condition, 2017 - 2029 (USD Billion) 7.4.5.2. Germany: Gout Therapeutics Market, by Drug Class, 2017 - 2029 (USD Billion) 7.4.6. Gout Therapeutics Market – Italy 7.4.6.1. Italy: Gout Therapeutics Market, by Disease Condition, 2017 - 2029 (USD Billion) 7.4.6.2. Italy: Gout Therapeutics Market, by Drug Class, 2017 - 2029 (USD Billion) 7.4.7. Gout Therapeutics Market – Spain 7.4.7.1. Spain: Gout Therapeutics Market, by Disease Condition, 2017 - 2029 (USD Billion) 7.4.7.2. Spain: Gout Therapeutics Market, by Drug Class, 2017 - 2029 (USD Billion) 7.4.8. Gout Therapeutics Market – Netherlands 7.4.8.1. Netherlands: Gout Therapeutics Market, by Disease Condition, 2017 - 2029 (USD Billion) 7.4.8.2. Netherlands: Gout Therapeutics Market, by Drug Class, 2017 - 2029 (USD Billion) 7.4.9. Gout Therapeutics Market – Austria 7.4.9.1. Austria: Gout Therapeutics Market, by Disease Condition, 2017 - 2029 (USD Billion) 7.4.9.2. Austria: Gout Therapeutics Market, by Drug Class, 2017 - 2029 (USD Billion) 7.4.10. Gout Therapeutics Market – Belgium 7.4.10.1. Belgium: Gout Therapeutics Market, by Disease Condition, 2017 - 2029 (USD Billion) 7.4.10.2. Belgium: Gout Therapeutics Market, by Drug Class, 2017 - 2029 (USD Billion) 7.5. Gout Therapeutics Market – Asia Pacific 7.5.1. Asia Pacific: Gout Therapeutics Market, by Disease Condition, 2017 - 2029 (USD Billion) 7.5.2. Asia Pacific: Gout Therapeutics Market, by Drug Class, 2017 - 2029 (USD Billion) 7.5.3. Gout Therapeutics Market – China 7.5.3.1. China: Gout Therapeutics Market, by Disease Condition, 2017 - 2029 (USD Billion) 7.5.3.2. China: Gout Therapeutics Market, by Drug Class, 2017 - 2029 (USD Billion) 7.5.4. Gout Therapeutics Market – India 7.5.4.1. India: Gout Therapeutics Market, by Disease Condition, 2017 - 2029 (USD Billion) 7.5.4.2. India: Gout Therapeutics Market, by Drug Class, 2017 - 2029 (USD Billion) 7.5.5. Gout Therapeutics Market – Malaysia 7.5.5.1. Malaysia: Gout Therapeutics Market, by Disease Condition, 2017 - 2029 (USD Billion) 7.5.5.2. Malaysia: Gout Therapeutics Market, by Drug Class, 2017 - 2029 (USD Billion) 7.5.6. Gout Therapeutics Market – Japan 7.5.6.1. Japan: Gout Therapeutics Market, by Disease Condition, 2017 - 2029 (USD Billion) 7.5.6.2. Japan: Gout Therapeutics Market, by Drug Class, 2017 - 2029 (USD Billion) 7.5.7. Gout Therapeutics Market – Indonesia 7.5.7.1. Indonesia: Gout Therapeutics Market, by Disease Condition, 2017 - 2029 (USD Billion) 7.4.5.1. - 6 -

  7. Gout Therapeutics Market Size Worth $7.63 Billion by 2029 | CAGR: 13.7% Indonesia: Gout Therapeutics Market, by Drug Class, 2017 - 2029 (USD Billion) 7.5.8. Gout Therapeutics Market – South Korea 7.5.8.1. South Korea: Gout Therapeutics Market, by Disease Condition, 2017 - 2029 (USD Billion) 7.5.8.2. South Korea: Gout Therapeutics Market, by Drug Class, 2017 - 2029 (USD Billion) 7.5.9. Gout Therapeutics Market – Australia 7.5.9.1. Australia: Gout Therapeutics Market, by Disease Condition, 2017 - 2029 (USD Billion) 7.5.9.2. Australia: Gout Therapeutics Market, by Drug Class, 2017 - 2029 (USD Billion) 7.6. Gout Therapeutics Market – Middle East & Africa 7.6.1. Middle East & Africa: Gout Therapeutics Market, by Disease Condition, 2017 - 2029 (USD Billion) 7.6.2. Middle East & Africa: Gout Therapeutics Market, by Drug Class, 2017 - 2029 (USD Billion) 7.6.3. Gout Therapeutics Market – Saudi Arabia 7.6.3.1. Saudi Arabia: Gout Therapeutics Market, by Disease Condition, 2017 - 2029 (USD Billion) 7.6.3.2. Saudi Arabia: Gout Therapeutics Market, by Drug Class, 2017 - 2029 (USD Billion) 7.6.4. Gout Therapeutics Market – UAE 7.6.4.1. UAE: Gout Therapeutics Market, by Disease Condition, 2017 - 2029 (USD Billion) 7.6.4.2. UAE: Gout Therapeutics Market, by Drug Class, 2017 - 2029 (USD Billion) 7.6.5. Gout Therapeutics Market – Israel 7.6.5.1. Israel: Gout Therapeutics Market, by Disease Condition, 2017 - 2029 (USD Billion) 7.6.5.2. Israel: Gout Therapeutics Market, by Drug Class, 2017 - 2029 (USD Billion) 7.6.6. Gout Therapeutics Market – South Africa 7.6.6.1. South Africa: Gout Therapeutics Market, by Disease Condition, 2017 - 2029 (USD Billion) 7.6.6.2. South Africa: Gout Therapeutics Market, by Drug Class, 2017 - 2029 (USD Billion) 7.7. Gout Therapeutics Market – Latin America 7.7.1. Latin America: Gout Therapeutics Market, by Disease Condition, 2017 - 2029 (USD Billion) 7.7.2. Latin America: Gout Therapeutics Market, by Drug Class, 2017 - 2029 (USD Billion) 7.7.3. Gout Therapeutics Market – Mexico 7.7.3.1. Mexico: Gout Therapeutics Market, by Disease Condition, 2017 - 2029 (USD Billion) 7.7.3.2. Mexico: Gout Therapeutics Market, by Drug Class, 2017 - 2029 (USD Billion) 7.7.4. Gout Therapeutics Market – Brazil 7.7.4.1. Brazil: Gout Therapeutics Market, by Disease Condition, 2017 - 2029 (USD Billion) 7.7.4.2. Brazil: Gout Therapeutics Market, by Drug Class, 2017 - 2029 (USD Billion) 7.7.5. Gout Therapeutics Market – Argentina 7.7.5.1. Argentina: Gout Therapeutics Market, by Disease Condition, 2017 - 2029 (USD Billion) 7.5.7.2. - 7 -

  8. Gout Therapeutics Market Size Worth $7.63 Billion by 2029 | CAGR: 13.7% Argentina: Gout Therapeutics Market, by Drug Class, 2017 - 2029 (USD Billion) 8.Competitive Landscape 8.1. Expansion and Acquisition Analysis 8.1.1. Expansion 8.1.2. Acquisitions 8.2. Partnerships/Collaborations/Agreements/Exhibitions 9.Company Profiles 9.1.Ablynx 9.1.1. Company Overview 9.1.2. Financial Performance 9.1.3. Product Benchmarking 9.1.4. Recent Development 9.2.Antares Pharma 9.2.1. Company Overview 9.2.2. Financial Performance 9.2.3. Product Benchmarking 9.2.4. Recent Development 9.3.Astellas Pharma 9.3.1. Company Overview 9.3.2. Financial Performance 9.3.3. Product Benchmarking 9.3.4. Recent Development 9.4.AstraZeneca 9.4.1. Company Overview 9.4.2. Financial Performance 9.4.3. Product Benchmarking 9.4.4. Recent Development 9.5.Boehringer Ingelheim 9.5.1. Company Overview 9.5.2. Financial Performance 9.5.3. Product Benchmarking 9.5.4. Recent Development 9.6.CymaBay Therapeutics 9.6.1. Company Overview 9.6.2. Financial Performance 9.6.3. Product Benchmarking 9.6.4. Recent Development 9.7.Eisai 9.7.1. Company Overview 9.7.2. Financial Performance 9.7.3. Product Benchmarking 9.7.4. Recent Development 9.8.Eli Lilly 9.8.1. Company Overview 9.8.2. Financial Performance 9.8.3. Product Benchmarking 9.8.4. Recent Development 9.9.GlaxoSmithKline 9.9.1. Company Overview 9.9.2. Financial Performance 7.7.5.2. - 8 -

  9. Gout Therapeutics Market Size Worth $7.63 Billion by 2029 | CAGR: 13.7% 9.9.3. Product Benchmarking 9.9.4. Recent Development 9.10. Horizon Pharma 9.10.1. 9.10.2. 9.10.3. 9.10.4. 9.11. JW Pharmaceutical 9.11.1. 9.11.2. 9.11.3. 9.11.4. 9.12. LG Life Sciences 9.12.1. 9.12.2. 9.12.3. 9.12.4. 9.13. Merck 9.13.1. 9.13.2. 9.13.3. 9.13.4. 9.14. Novartis 9.14.1. 9.14.2. 9.14.3. 9.14.4. 9.15. Novo Nordisk 9.15.1. 9.15.2. 9.15.3. 9.15.4. 9.16. Regeneron Pharmaceuticals 9.16.1. Company Overview 9.16.2. Financial Performance 9.16.3. Product Benchmarking 9.16.4. Recent Development 9.17. Sandoz 9.17.1. Company Overview 9.17.2. Financial Performance 9.17.3. Product Benchmarking 9.17.4. Recent Development 9.18. Takeda Pharmaceuticals 9.18.1. Company Overview 9.18.2. Financial Performance 9.18.3. Product Benchmarking 9.18.4. Recent Development 9.19. Teijin Pharma 9.19.1. Company Overview 9.19.2. Financial Performance 9.19.3. Product Benchmarking Company Overview Financial Performance Product Benchmarking Recent Development Company Overview Financial Performance Product Benchmarking Recent Development Company Overview Financial Performance Product Benchmarking Recent Development Company Overview Financial Performance Product Benchmarking Recent Development Company Overview Financial Performance Product Benchmarking Recent Development Company Overview Financial Performance Product Benchmarking Recent Development - 9 -

  10. Gout Therapeutics Market Size Worth $7.63 Billion by 2029 | CAGR: 13.7% 9.19.4. 9.20. 9.20.1. 9.20.2. 9.20.3. 9.20.4. Recent Development Vertex Pharmaceuticals Company Overview Financial Performance Product Benchmarking Recent Development ➢Access Press Release on Gout Therapeutics Market: https://www.polarismarketresearch.com/press-releases/global-gout-therapeutics-market ➢About Polaris Market Research Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors, and chemicals among various other industries present around the world. We strive to provide our customers with updated information on innovative technologies, high growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to our customers. E mail Id: sales@polarismarketresearch.com Web: www.polarismarketresearch.com Official Blog: http://polarismarketresearch.blogspot.com - 10 -

More Related